Physician profile
Manuel Marrufo
NPI 1205863644
$2,916.28
in general payments reported to CMS, 2019-2025
30 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,849 · 2020: $312 · 2021: $135 · 2022: $85.72 · 2023: $16.41 · 2024: $239 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.91 | 2019-2025 | |
| Ucb, INC. | $370.50 | 2019-2025 | Zilbrysq, Briviact |
| Biogen, INC. | $243.74 | 2019-2024 | Vumerity |
| Amneal Pharmaceuticals LLC | $216.23 | 2019-2025 | Crexont |
| Supernus Pharmaceuticals, INC. | $163.07 | 2019 | |
| Avanir Pharmaceuticals, INC. | $148.10 | 2019-2020 | |
| Lilly USA, LLC | $146.45 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $138.20 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $136.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $131.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $127.47 | 2019-2020 | |
| Csl Behring | $102.04 | 2020-2025 | Hizentra |
| Lundbeck LLC | $73.38 | 2019-2020 | |
| Emd Serono, INC. | $66.50 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $56.46 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akcea Therapeutics, INC. | $38.20 | 2019 | |
| Amgen INC. | $35.73 | 2025 | Uplizna |
| Assertio Therapeutics, INC. | $35.50 | 2019 | |
| Upsher-Smith Laboratories LLC | $33.37 | 2019 | |
| Acorda Therapeutics, INC | $32.73 | 2019 | |
| Pfizer INC. | $27.71 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $27.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.03 | 2019 | |
| Eisai INC. | $20.59 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.65 | 2025 | |
| Medtronic USA, INC. | $16.27 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.14 | 2025 | Acthar |
| Kyowa Kirin, INC. | $14.85 | 2024 | Nourianz |
| Tg Therapeutics, INC. | $13.88 | 2025 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Marrufo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.